RxDoctor Payments Data

Henry Shapiro, MD

Hematology & Oncology · Jupiter, FLNPI 1477591709

Payments from drug & device makers

$11,985in general payments, 2019–2025

Across 682 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Bristol Myers Squibb$731
  • AstraZeneca$690
  • Johnson & Johnson$689
  • Incyte Corporation$595
  • Astellas Pharma US Inc$593
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$11,60897%
  • Education$3773%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer124$1,230
Bristol Myers Squibb60$731
AstraZeneca(2 entities)37$690
Johnson & Johnson33$689
Incyte Corporation31$595
Astellas Pharma US Inc26$593
Sanofi23$553
Genentech USA, Inc.34$516
Merck23$448
Novartis23$416
Daiichi Sankyo Inc.16$369
E.r. Squibb & Sons, L.L.C.19$315
AbbVie16$292
Amgen15$274
Seagen Inc.11$271
Array Biopharma Inc16$269
Lilly USA, LLC13$237
GSK11$226
Takeda Pharmaceuticals U.S.A., Inc.9$219
Bayer10$193
Ipsen Biopharmaceuticals, Inc8$169
Eisai Inc.12$163
Sobi, Inc5$161
Pharmacyclics LLC, An Abbvie Company8$153
Beigene USA, Inc.6$137
Rigel Pharmaceuticals, Inc.6$132
Adaptive Biotechnologies Corporation5$120
Sirtex Medical Inc1$111
Gilead(2 entities)5$106
Puma Biotechnology, Inc.6$98
Caris MPI, Inc.3$96
Foundation Medicine, Inc.2$93
Stemline Therapeutics Inc.4$92
Amneal Pharmaceuticals LLC4$88
AVEO Pharmaceuticals, Inc.3$76
Geron Corporation3$67
Exelixis Inc.3$62
Pharmaessentia USA Corporation2$60
Boehringer Ingelheim3$58
Regeneron Healthcare Solutions, Inc.3$56
Servier Pharmaceuticals LLC2$49
EMD Serono, Inc.2$47
Karyopharm Therapeutics Inc.3$41
Legend Biotech USA Inc.2$40
TG Therapeutics, Inc.2$39
CTI Biopharma Corp.2$39
Dendreon Pharmaceuticals LLC1$35
Deciphera Pharmaceuticals Inc.2$34
Mirati Therapeutics, Inc.2$33
Jazz Pharmaceuticals Inc.2$31
Beone Medicines USA, Inc.1$30
Morphosys, US Inc.2$30
Pharmaand GmbH2$28
Tolmar, Inc.1$27
Pharmacosmos Therapeutics Inc.1$26
Biocon Biologics Inc1$24
Fennec Pharmaceuticals, Inc.1$22
Kyowa Kirin, Inc.1$21
Verity Pharmaceuticals Inc.1$20
Immunogen, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,985 in reported general payments places this provider in the 45th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$1,967,327
Medicare patients
356
Services billed
141,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate36$550,330
PomalystPomalidomide21$452,016
JakafiRuxolitinib Phosphate20$361,227
Lenalidomide18$245,659
BrukinsaZanubrutinib14$212,524
PromactaEltrombopag Olamine11$194,729
ProcritEpoetin Alfa14$61,481
EliquisApixaban62$41,049
XareltoRivaroxaban12$12,191
OzempicSemaglutide11$8,310
Tamoxifen Citrate22$861
Diclofenac Sodium13$482
Dexamethasone14$272
Letrozole17$256
Prednisone62$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$690$550,33036 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$315$452,01621 claims
Incyte CorporationJakafi$595$361,22720 claims
Beigene USA, Inc.Brukinsa$137$212,52414 claims
NovartisPromacta$416$194,72911 claims
Johnson & JohnsonProcrit, Xarelto$689$73,67226 claims
PfizerEliquis$1,230$41,04962 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →